Biolevate raises €30 million to scale AI for life-sciences workflows

Biolevate’s new funding is a bet on making scientific and regulatory work easier to manage at scale. The Paris-based company announced a €30 million Series A on 22 September 2026 and is using the round to develop its life-sciences AI platform and expand internationally.24

Who invested in Biolevate?

RAISE France, the investment vehicle of entrepreneur Aymar Hénin, and Orange Ventures co-led the round. MSD Global Health Innovation Fund, Station F and returning investor EQT Ventures also participated.24 Biolevate previously raised a €6 million seed round in November 2024, putting the two announced rounds at €36 million combined.4

Industry coverage identifies Joël Belafa and Nathan Chen as Biolevate’s founders.3 Belafa, its CEO, was previously Director of Engineering at Dataiku, according to Biolevate’s company profile.24 The available sources do not establish the background of every founding-team member.

What is Biolevate building?

Biolevate describes its mission as knowledge-driven automation for life-sciences operations. Its enterprise AI platform is designed to turn scientific and regulatory knowledge into workflows that retain supporting evidence and can be audited—a distinction that matters when teams must review the basis for an output, not merely receive a generated answer.34 Reporting also describes human oversight as part of the intended approach, though the available excerpts do not explain precisely how its review and source-tracing controls work.12

The company initially focused on regulatory approval workflows and has since broadened the platform’s scope, according to industry coverage.3 Tech.eu reports that it can run up to 100,000 AI agents concurrently.2 That is a reported platform capacity, not evidence that every customer deployment operates at that scale.

Biolevate has reported literature reviews running 16 times faster and an 80% efficiency gain in regulatory intelligence and compliance.10 The available sources do not provide testing conditions or independent validation for those figures, so they should be read as reported results rather than established benchmarks.

What changes after the round?

Biolevate intends to deepen product capabilities, scale deployments and pursue international growth.29 Reports published alongside the financing say it had already opened a Boston office, rather than merely planning one.78 Orange has also announced an investment through Orange Ventures and described plans for Orange Business to combine Biolevate’s automation with Enovalife’s clinical-research and integration expertise.23

On commercial traction, Biolevate says more than 12 enterprise customers use its platform in production and that annual recurring revenue grew twentyfold over the preceding year. It has not disclosed the starting or ending ARR figure in the available coverage.8 The funding and customer figures point to a company moving beyond its seed stage; they do not, on their own, verify its technical performance claims.